Showing 141-150 of 186 results for "".
Manage and Prevent Isotretinoin Side Effects
https://practicaldermatology.com/topics/general-topics/PD0409_01-php/22839/This guide will help you anticipate and prevent or minimize side effects that your patients can develop as a result of isotretinoin therapy.- Johnson & Johnson Consumer to Acquire NeoStratahttps://practicaldermatology.com/news/johnson-johnson-consumer-to-to-acquire-neostrata/2458589/Johnson & Johnson Consumer, Inc. has entered into a definitive agreement to acquire NeoStrata Company, Inc. The acquisition will include NeoStrata's affiliates and parent company TriStrata, Incorporated, a privately-held compan
- EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challengehttps://practicaldermatology.com/news/epigencare-named-as-johnson-johnson-innovation-finalist-in-skincare-challenge/2457829/EpigenCare Inc., a personalized skincare startup company, is a finalist in Johnson & Johnson Innovation’s Digital Beauty Quickfire Challenge. The Challenge
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis
- Johnson & Johnson Announces Kenvue as the Name for New Consumer Health Companyhttps://practicaldermatology.com/news/johnson-johnson-announces-kenvue-as-the-name-for-new-consumer-health-company/2461363/Johnson & Johnson’s planned new consumer health company will be named...Kenvue. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” ref
- Johnson & Johnson Acquires Proteologix, Maker of Atopic Dermatitis Candidate, for $850 Millionhttps://practicaldermatology.com/news/johnson-johnson-acquires-proteologix-maker-atopic-dermatitis-candidate-850-million/2463090/Johnson & Johnson has entered into a definitive agreement to acquire biotech company Proteologix for $850 million in cash, with potential for an additional milestone payment. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to ente
- Johnson & Johnson Consumer Health Research Sheds Light on the Development of the Skin Microbiomehttps://practicaldermatology.com/news/johnson-johnson-consumer-health-research-sheds-light-on-the-development-of-the-skin-microbiome/2460428/New Johnson & Johnson Consumer Health research provides key insights into how the infant microbiome develops from birth to childhood. The findings, based on 10 years of data, were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020.
- New AAD, Industry Collab to Increase Number of Black, Latino, and Indigenous Physicians in Dermatologyhttps://practicaldermatology.com/news/new-aad-industry-collab-to-increase-number-of-black-latino-and-indigenous-physicians-in-dermatology/2461120/The American Academy of Dermatology (AAD) in collaboration with Johnson & Johnson Consumer Health and the Janssen Pharmaceutical Companies of Johnson & Johnson is launching “Pathways: Inclusivity in Dermatology” to increase the number of practicing dermatologists in the U.S. w
- Calling all Innovators: J & J Launches Digital Beauty QuickFire Challengehttps://practicaldermatology.com/news/calling-all-innovators-j-j-launches-digital-beauty-quickfire-challenge/2457975/Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., is launching the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digital
- AMBI Now Part of Valeant Pharmaceuticalshttps://practicaldermatology.com/news/20121221-ambi_now_part_of_valeant_pharmaceuticals/2459653/Johnson & Johnson has sold the AMBI brand to Valeant Pharmaceuticals North America. Valeant is a multinational, pharmaceutical/OTC company based in Bridgewater, NJ.